Better Growth Stock: Abbott vs. AbbVie
Abbott Laboratories (NYSE: ABT) and (NYSE: ABBV) share a common past. About a decade ago, Abbott spun out its pharmaceuticals business into a separate company to create AbbVie. Since then, both companies have grown revenue and net income in the triple digits. At the same time, they've steadily increased dividends year after year, offering shareholders passive income growth too.
After last year's stock market gains, you may be looking toward the next bull market and aiming to prepare by scooping up growth stocks. Both Abbott and AbbVie could fit into your strategy. But, if you could only buy one, which should you choose? Let's find out which one of these healthcare companies makes the better growth stock to buy now.
Source Fool.com
AbbVie Inc. Stock
With 34 Buy predictions and not a single Sell prediction AbbVie Inc. is an absolute favorite of our community.
With a target price of 180 € there is a slightly positive potential of 3.77% for AbbVie Inc. compared to the current price of 173.46 €.